Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Remoxy's "Complete Response" Letter Has No Clear Culprit But Many Suspects

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer's abuse-deterrent, extended-release form of pain drug oxycodone faces legal, regulatory and manufacturing challenges.

You may also be interested in...



Deal Watch: Bristol Adds To Oncology Pipeline With F-star Alpha Option Pact

Novartis completes the divestiture of its vaccines business by selling off two influenza vaccines to Australia’s CSL Ltd. Zogenix buys out Britain’s Brabant pharma and Pain Therapeutics is searching for a new partner for Remoxy after Pfizer drops the abuse-deterrent opioid.

Remoxy Development Not ‘Unmitigated Disaster,’ CEO Reassures; Hunt Begins For New Partner

Pfizer terminates agreement with Pain Therapeutics after reviewing top-line results of five studies done to address FDA complete response letter; Pain says data supports refiling of NDA for its abuse-deterrent long-acting oxycodone formulation by mid-2015.

Opioid Market Snapshot: No Pain, No Gain For Abuse-Deterrence Claims

Abuse-deterrent opioids address a serious unmet need and help differentiate brands from the field of generics, but so far Purdue’s OxyContin remains the only opioid on the market with abuse-deterrent claims, even though FDA recently approved two new opioid analgesics.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072423

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel